SNY catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
December 2026
- Primary completion Dec 1, 2026Sponsor estimatePhase 2NCT06832865ELISA in Relapsed/Refractory MMMassachusetts General Hospital · Relapsed Refractory Multiple Myeloma (RRMM)RecruitingPFECollaboratorSNYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2026Sponsor estimatePhase 1/Phase 2NCT06907511Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic...Sanofi · Pandemic Influenza ImmunizationActive, not recruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 17, 2026Sponsor estimatePhase 2NCT06958536A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's DiseaseSanofi · Crohn's DiseaseRecruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 17, 2026Sponsor estimatePhase 2NCT06975722A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative ColitisSanofi · Ulcerative ColitisActive, not recruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 23, 2026Sponsor estimatePhase 2NCT06500702A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary...Sanofi · Focal Segmental GlomerulosclerosisRecruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 2NCT04883242Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple MyelomaUniversity of Washington · Recurrent Multiple MyelomaActive, not recruitingSNYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Jan 18, 2027Sponsor estimate | NCT06686654Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based...Sanofi Pasteur, a Sanofi Company · Human Metapneumovirus Immunization | SNYLead | Phase 1/Phase 2 | Active, not recruiting | Locked | Locked | Locked |
| Jan 19, 2027Sponsor estimate | NCT05584670A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid TumorsSanofi · Solid Tumor | SNYLead | Phase 1/Phase 2 | Recruiting | Locked | Locked | Locked |
- Primary completion Jan 18, 2027Sponsor estimatePhase 1/Phase 2NCT06686654Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based...Sanofi Pasteur, a Sanofi Company · Human Metapneumovirus ImmunizationActive, not recruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 19, 2027Sponsor estimatePhase 1/Phase 2NCT05584670A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid TumorsSanofi · Solid TumorRecruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
February 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Feb 9, 2027Sponsor estimate | NCT07170917Brivekimig for the Treatment of Moderate to Severe Hidradenitis SuppurativaSanofi · Hidradenitis Suppurativa | SNYLead | Phase 2 | Recruiting | Locked | Locked | Locked |
| Feb 11, 2027Sponsor estimate | NCT06984627A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' DiseaseSanofi · Graves' Disease | SNYLead | Phase 2 | Recruiting | Locked | Locked | Locked |
- Primary completion Feb 9, 2027Sponsor estimatePhase 2NCT07170917Brivekimig for the Treatment of Moderate to Severe Hidradenitis SuppurativaSanofi · Hidradenitis SuppurativaRecruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 11, 2027Sponsor estimatePhase 2NCT06984627A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' DiseaseSanofi · Graves' DiseaseRecruitingSNYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 10 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.